The relationship between mental health reforms and general population suicide rates in Australia over the past three and a half decades: 1987-2021.

Nearly 3,000 Australians tragically end their lives by suicide each year, underscoring a major national public health challenge with substantial socio-economic ramifications. Australia's National Mental Health Plans (NMHPs) aim to improve mental health and reduce suicide rates. This study investigates their effectiveness by analyzing how age-standardized suicide rates across Australian jurisdictions have fluctuated alongside the implementation of five NMHPs from 1987 to 2021. Findings reveal mixed impacts, with some plans linked to decreases and others associated with increases in suicide rates across different periods and regions. Notably, the recent decline in 2020 requires careful consideration amidst COVID-19 pandemic influences. These insights not only provide valuable evidence for shaping future mental health policies and initiatives but also for future health services research.

Changes in Healthcare Spending Attributable to High Deductible Health Plan Offer Among Enrollees with Comorbid Substance Use Disorder and Cardiovascular Disease.

BACKGROUND: The rise in prevalence of high deductible health plans (HDHPs) in the United States may raise concerns for high-need, high-utilization populations such as those with comorbid chronic conditions. In this study, we examine changes in total and out-of-pocket (OOP) spending attributable to HDHPs for enrollees with comorbid substance use disorder (SUD) and cardiovascular disease (CVD). METHODS: We used de-identified administrative claims data from 2007 to 2017. SUD and CVD were defined using algorithms of ICD 9 and 10 codes and HEDIS guidelines. The main outcome measures of interest were spending measure for all non-SUD/CVD-related services, SUD-specific services, and CVD-specific services, for all services and medications specifically. We assessed both total and OOP spending. We used an intent-to-treat two-part model approach to model spending and computed the marginal effect of HDHP offer as both the dollar change and percent change in spending attributable to HDHP offer. RESULTS: Our sample included 33,684 enrollee-years and was predominantly white and male with a mean age of 53 years. The sample had high demonstrated substantial healthcare utilization with 94% using any non-SUD/CVD services, and 84% and 78% using SUD and CVD services, respectively. HDHP offer was associated with a 17.0% (95% CI = [0.07, 0.27] increase in OOP spending for all non-SUD/CVD services, a 21.1% (95% CI = [0.11, 0.31]) increase in OOP spending for all SUD-specific services, and a 13.1% (95% CI = [0.04, 0.23]) increase in OOP spending for all CVD-specific services. HDHP offer was also associated with a significant increase in OOP spending on non-SUD/CVD-specific medications and SUD-specific medications, but not CVD-specific medications. CONCLUSIONS: This study suggests that while HDHPs do not change overall levels of annual spending among enrollees with comorbid CVD and SUD, they may increase the financial burden of healthcare services by raising OOP costs, which could negatively impact this high-need and high-utilization population.

Deductible imputation in administrative medical claims datasets.

OBJECTIVE: To validate imputation methods used to infer plan-level deductibles and determine which enrollees are in high-deductible health plans (HDHPs) in administrative claims datasets. DATA SOURCES AND STUDY SETTING: 2017 medical and pharmaceutical claims from OptumLabs Data Warehouse for US individuals <65 continuously enrolled in an employer-sponsored plan. Data include enrollee and plan characteristics, deductible spending, plan spending, and actual plan-level deductibles. STUDY DESIGN: We impute plan deductibles using four methods: (1) parametric prediction using individual-level spending; (2) parametric prediction with imputation and plan characteristics; (3) highest plan-specific mode of individual annual deductible spending; and (4) deductible spending at the 80th percentile among individuals meeting their deductible. We compare deductibles' levels and categories for imputed versus actual deductibles. DATA COLLECTION/EXTRACTION METHODS: Not applicable. PRINCIPAL FINDINGS: All methods had a positive predictive value (PPV) for determining high- versus low-deductible plans of ≥87%; negative predictive values (NPV) were lower. The method imputing plan-specific deductible spending modes was most accurate and least computationally intensive (PPV: 95%; NPV: 91%). This method also best correlated with actual deductible levels; 69% of imputed deductibles were within $250 of the true deductible. CONCLUSIONS: In the absence of plan structure data, imputing plan-specific modes of individual annual deductible spending best correlates with true deductibles and best predicts enrollees in HDHPs.

Association of High-Deductible Health Plans With Health Care Use and Costs for Patients With Cardiovascular Disease.

Background By increasing cost sharing, high-deductible health plans (HDHPs) aim to reduce low-value health care use. The association of HDHPs with health care use and costs in patients with chronic cardiovascular disease is unknown. Methods and Results This longitudinal cohort study analyzed 57 690 privately insured patients, aged 18 to 64 years, from a large commercial claims database with chronic cardiovascular disease from 2011 to 2019. Health care entities in which all or most beneficiaries switched from being in a traditional plan to an HDHP were identified. A difference-in-differences design was used to account for differences between individuals who remained in traditional plans and those who switched to HDHPs and to assess changes in health care use and costs. Among the 934 individuals in the HDHP group and the 56 756 in the traditional plan group, switching to an HDHP was not associated with statistically significant changes in annual outpatient visits, hospitalizations, or emergency department visits (-8.3% [95% CI, -16.8 to 1.1], -28.5% [95% CI, -62.1 to 34.6], and 11.2% [95% CI, -20.9 to 56.5], respectively). Switching to an HDHP was associated with an increase of $921 (95% CI, $743-$1099) in out-of-pocket costs but no statistically significant difference in total health care costs. Conclusions Among commercially insured patients with chronic cardiovascular disease, switching to an HDHP was not associated with a change in health care use but was associated with an increase in out-of-pocket costs. Although health care use by individuals with chronic cardiovascular disease may not be sensitive to higher cost sharing associated with HDHP enrollment, there may be a significant increase in patients' financial burden.

Desafios e perspectivas da saúde suplementar: notas sobre o estado da arte na jurisprudência do Supremo Tribunal Federal e do Superior Tribunal de Justiça / Challenges and perspectives of supplementary health: notes on the state of the art in the jurisprudence of the Supreme Court and the Superior Court of Justice / Retos y perspectivas de la salud suplementaria: notas sobre el estado del arte en la jurisprudencia del Supremo Tribunal Federal y del Superior Tribunal de Justicia

Objetivo: analisar as perspectivas e os desafios na concretização do dever de garantir a mais completa assistência no campo da saúde suplementar. Metodologia: pesquisa qualitativa de natureza descritiva, que analisou acervo documental composto pelos principais diplomas legais relacionados ao campo da saúde suplementar e a evolução da jurisprudência do Supremo Tribunal Federal e do Superior Tribunal de Justiça nessa área, notadamente sobre o fornecimento de medicamentos não registrados pela Anvisa ou uso off label de remédios registrados, e acerca da taxatividade mitigada do rol da ANS. Resultados: as avenças firmadas entre os planos de saúde e os beneficiários configuram relação contratual na qual o consumidor é a parte vulnerável, mas, por outro lado, detém informações que não são de conhecimento da operadora. Esta, por sua vez, detém conhecimentos técnicos sobre moléstias e tratamentos muito além da compreensão de um consumidor comum. Nesse mercado, em que predomina a assimetria informacional, avulta a importância da firme atuação da agência reguladora, entidade capaz de equilibrar o sistema, dando tratamento uniforme a questões que devem ser globalmente consideradas, tendo em vista a massa de consumidores de planos de saúde, levando em conta as especificidades de cada tipo de contrato, individual ou coletivo, anterior ou posterior à Lei nº 9.656/1998.Conclusão: a atuação do Legislativo deve levar em conta o delicado equilíbrio entre as necessidades e as possibilidades, bem como as características inerentes ao caráter privado da prestação, de forma suplementar, de serviços de natureza pública, ao passo que a intervenção do Judiciário para infirmar decisões da agência reguladora justifica-se apenas em casos de clara ilegalidade e, sobretudo, deve levar em conta a globalidade do sistema regulado, o que nem sempre é facilmente perceptível à vista de casos individualmente considerados.

Objective: to analyze the perspectives and challenges in the realization of the duty to guarantee the most complete assistance in the field of supplementary health. Methods: qualitative research of descriptive nature that analyzed documentary collection composed of the main legal diplomas related to the field of supplementary health and the evolution of jurisprudence of the Supreme Court and the Superior Court of Justice in this area, especially about the supply of medicines not registered by Anvisa or off label use of registered medicines, and about the mitigated taxation of the ANS list. Results: the agreements signed between the health plans and the beneficiaries configure contractual relationship in which the consumer is the vulnerable party, but, on the other hand, holds information that is not known to the operator. This, in turn, has technical knowledge about diseases and treatments far beyond the understanding of a common consumer. In this market, in which information asymmetry predominates, the importance of the firm action of the regulatory agency, an entity capable of balancing the system, giving uniform treatment to issues that should be considered globally, in view of the mass of consumers of health plans, taking into account the specificities of each type of contract, individual or collective, before or after Bill9, 656/1998. Conclusion: the Legislative action must take into account the delicate balance between needs and possibilities, as well as the characteristics inherent in the private character of the provision, in a supplementary nature, of services of a public nature, whereas intervention by the judiciary to rule against decisions of the regulatory agency is justified only in cases of clear illegality and, above all, must take into account the whole of the regulated system, which is not always easily perceived in view of individual cases.

Objetivo: analizar las perspectivas y los desafíos en la realización del deber de garantizar la más completa asistencia en el campo de la salud complementaria. Metodología: investigación cualitativa de naturaleza descriptiva que analizó acervo documental compuesto por los principales diplomas legales relacionados al campo de la salud complementaria y la evolución de la jurisprudencia del Supremo Tribunal Federal y del Superior Tribunal de Justicia en esa área, especialmente sobre el suministro de medicamentos no registrados por la Anvisa o uso fuera de etiqueta de remedios registrados, y acerca de la taxactividad mitigada del rol de la ANS. Resultados: las avencias firmadas entre los planes de salud y los beneficiarios configuran relación contractual en la cual el consumidor es la parte vulnerable, pero, por otro lado, posee informaciones que no son de conocimiento del operador. Ésta, a su vez, posee conocimientos técnicos sobre enfermedades y tratamientos mucho más allá de la comprensión de un consumidor común. En este mercado, en el que predomina la asimetría informacional, la importancia de la firme actuación de la agencia reguladora, capaz de equilibrar el sistema, dando tratamiento uniforme a cuestiones que deben ser consideradas globalmente, teniendo en cuenta las especificidades de cada tipo de contrato, individual o colectivo, anterior o posterior a la Ley 9.656/1998. Conclusión: la actuación del Legislativo debe tener en cuenta el delicado equilibrio entre las necesidades y las posibilidades, así como las características inherentes al carácter privado de la prestación, en carácter suplementario, de servicios de carácter público, mientras que la intervención del poder judicial para invalidar las decisiones de la agencia reguladora sólo se justifica en casos de clara ilegalidad y, sobre todo, debe tener en cuenta la totalidad del sistema regulado, lo que no siempre es fácilmente perceptible a la vista de casos individuales considerados.

Role of prices in driving the variation in spending across medical groups.

OBJECTIVE: To understand the relative role of prices versus utilization in the variation in total spending per patient across medical groups. DATA SOURCES: We conducted a cross-sectional analysis of medical claims for commercially insured adults from a large national insurer in 2018. STUDY DESIGN: After assigning patients to a medical group based on primary care visits in 2018, we calculated total medical spending for each patient in that year. Total spending included care provided by clinicians within the medical group and care provided by other providers, including hospitals. It did not include drug spending. We estimated the case mix adjusted spending per patient for each medical group. Within each market, we categorized medical groups into quartiles based on the group's spending per patient. To decompose spending variation into price versus utilization, we compared spending differences between highest and lowest quartile medical groups under two scenarios: (1) using actual prices (2) using a standardized price (same price used for a given service across the nation). PRINCIPAL FINDINGS: In total, 3,921,736 patients were assigned to 7284 medical groups. Per-patient spending in the highest quartile of spending medical groups was $1813 higher than per-patient spending in the lowest spending quartile of medical groups (50% higher relative spending). This overall difference was primarily driven by differences in inpatient care, imaging, and specialty care. In the scenario where we used standardized prices, the difference in spending between medical groups in the top and bottom quartiles decreased to $1425, implying that 79% of the $1813 difference in spending between the top and bottom quartile groups is explained by utilization and the remaining 21% by prices. The likely explanation for the modest impact of prices is that patients cared for by a given medical group receive care across a wide range of providers. CONCLUSIONS: Prices explained a modest fraction of the differences in spending between medical groups.

The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets.

Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform decisions about access and reimbursement. We study how CE thresholds imposed by a health plan for granting reimbursement affect drug producers' pricing incentives and patients' access to new drugs. Analysing a sequential pricing game between an incumbent drug producer and a potential entrant with a new drug, we show that CE thresholds may have adverse effects for payers and patients. A stricter CE threshold may induce the incumbent to switch pricing strategy from entry accommodation to entry deterrence, limiting patients' access to the new drug. Otherwise, irrespective of whether entry is deterred or accommodated, a stricter CE threshold is never pro-competitive and may in fact facilitate a collusive outcome with higher prices of both drugs. Compared to a laissez-faire policy, the use of CE thresholds when an incumbent monopolist is challenged by therapeutic substitutes can only increase the surplus of a health plan if it leads to entry deterrence. In this case the price reduction by the incumbent necessary to deter entry outweighs the health loss to patients who do not get access to the new drug.

The role of health plans in addressing the opioid crisis: A qualitative study.

INTRODUCTION: Health plans are key players in substance use treatment in the United States, and the opioid crisis presents new challenges for them. This article is part of the HEALing Communities Study (HCS) funded by NIH, which seeks to facilitate communities' adoption of activities that might reduce overdose deaths, including overdose prevention education and naloxone distribution, medication for opioid use disorder, and safer opioid prescribing. We examine how health plans in one state (Massachusetts) are adapting to encourage and sustain activities that help communities to address opioid use disorder (OUD). METHODS: We conducted semi-structured interviews with managers of behavioral health services at eight health plans in Massachusetts that that have Medicare, Medicaid, and commercial lines of business. Two plans in this sample contract with a specialized behavioral health organization ("carve-out"). The interviewees also completed a survey on policies regarding access to treatment and opioid prescribing. Interviews were recorded and transcribed and analyzed using thematic analysis. Analysis of the data included intended influence of the policies at three levels: member level (micro), group or community level (meso), and system or institutional level (macro). RESULTS: All health plans developed strategies to increase access to treatment for OUD, primarily through eliminating or decreasing cost-sharing, eliminating pre-authorization for MOUD, and increasing supply of providers. Health plans encourage qualified practitioners to offer MOUD, but most do not provide incentives or training. Identifying high risk populations is a focus of health plans in this sample. Naloxone is a covered benefit in all health plans, although with variation in monthly limits and cost-sharing. Most health plans take measures to influence opioid prescribing. Health plans' activities are predominately aimed at the micro (member) level with little ability to influence at the macro (wider system-level changes). CONCLUSION: This study provides insight into how health plans develop strategies to address the rise in OUD and fatal opioid overdoses, many of which are key in the HCS initiative. How active a role health plans play in addressing the opioid crisis varies, even within the insurance industry in one state (Massachusetts).

Engaging health plans to prioritize HPV vaccination and initiate at age 9.

Health plans can influence pediatric and primary care providers and patients to understand HPV vaccination coverage and increase HPV vaccination uptake. By initiating vaccination at age nine, health plans can lay the groundwork for on-time HPV cancer prevention by age 13. In 2022, the American Cancer Society engaged 28 health plans in a 12-month HPV vaccination learning collaborative in which plans set their own quality improvement targets, implemented multi-pronged interventions, and joined quarterly best-practice sharing calls. Twenty-five of the 28 plans reported including a focus on ages 9 to 10. Preliminary pre-intervention data illustrate that vaccination rates from participating plans follow national trends and reaffirm existing gaps for HPV vaccination. Health plan interventions to address HPV vaccination are consistent with best practices but could be maximized to target initiation at ages 9-10 by using provider and patient reminders, targeted provider education, and dose-specific provider pay for performance and patient incentive programs. Health plans should explore future capacity to analyze non-HEDIS required data, including HPV initiation and HPV vaccination data for adolescents below age 13.

Secret Shopper Analysis Shows Getting Psychiatry Appointment in New York City is Well Kept Secret.

OBJECTIVE: The Mental Health Parity and Addiction Equity Act prevents payors from imposing more stringent limitations on mental health and substance disorder benefits than medical and surgical benefits. In this study, we assess a New York City insurer's parity compliance based on the accuracy and validity of network-provided information and a consider legal framework to address this. METHODS: A "secret shopper" analysis was performed, in which researchers attempted to contact the 192 psychiatrist providers listed in the 2019 online directory of United Healthcare psychiatry providers. RESULTS: Only 3.1% of calls resulted in researchers booking an appointment. 50.5% of calls resulted in "no response", 18.75% connected to psychiatrists not accepting new patients, and 8.8% of listed providers stated they were not in the United Healthcare network. CONCLUSIONS: Erroneous directory information exacerbates the issue of access to mental health treatment. Enforcement policy should hold insurers accountable for the reliability of their online directories.

The December Effect in Pediatric Elective Surgery Utilization: Differences Between Privately and Publicly Insured Children.

OBJECTIVES: The objective of this study was to identify differences in December elective surgery utilization between privately and publicly insured children, given that increases in the prevalence and size of annual deductibles may be driving more families with commercial health insurance to delay elective pediatric surgical procedures until later in the calendar year. STUDY DESIGN: We identified patients aged <18 years who underwent myringotomy, tonsillectomy ± adenoidectomy, tympanoplasty, hydrocelectomy, orchidopexy, distal hypospadias repair, or repair of inguinal, umbilical, or epigastric hernia using the 2012-2019 state inpatient and ambulatory surgery and services databases of 9 states. Log-binomial regression models were used to compare relative probabilities of procedures being performed each month. Linear regression models were used to evaluate temporal trends in the proportions of procedures performed in December. RESULTS: Our study cohort (n = 1 001 728) consisted of 56.7% privately insured and 41.8% publicly insured children. Peak procedure utilization among privately and publicly insured children was in December (10.1%) and June (9.6%), respectively. Privately insured children were 24% (95% CI 22%-26%) more likely to undergo surgery in December (P < .001), with a significant increase seen for 8 of 9 procedures. There was no trend over time in the percentage of procedures performed in December, except for hydrocelectomies, which increased by 0.4 percentage points/year among privately insured children (P = .02). CONCLUSIONS: Privately insured children are >20% more likely than publicly insured children to undergo elective surgery in December. However, despite increases in the prevalence of high deductibles, the proportion of procedures performed in December has not increased over recent years.

O desenvolvimento do projeto terapêutico singular na saúde mental: revisão integrativa / The development of the singular therapeutic project in mental health: integrative review / El desarrollo del proyecto terapéutico singular en salud mental: revisión integradora

O Projeto Terapêutico Singular constitui-se como uma das principais estratégias de cuidado em saúde mental, pois é pautada em uma clínica que acolhe, aposta na formação de vínculos e promove a continuidade do cuidado ao usuário. O presente estudo tem como objetivo identificar quais as evidências científicas sobre o desenvolvimento do Projeto Terapêutico Singular na saúde mental. Trata-se de uma revisão integrativa da literatura, realidade no período do mês de julho a outubro de 2022. Para a formulação da questão de pesquisa, utilizou-se a estratégia do acrônimo PICo, resultando na seguinte pergunta: quais as evidências científicas sobre o desenvolvimento do Projeto Terapêutico Singular na Saúde Mental? Os resultados encontrados apontam que o mesmo apresenta potencialidades e desafios quanto ao seu desenvolvimento no âmbito da saúde mental. O cuidado compartilhado e a formação de vínculo com o usuário apresentaram-se como fatores importantes para o desenvolvimento do instrumento. Entende-se que as inovações do cuidado em saúde mental, tais como a clínica ampliada e o desenvolvimento do Projeto Terapêutico Singular, possibilitam a inclusão social da loucura e da diferença em diferentes espaços do contexto social e cultural.

The Singular Therapeutic Project is one of the main strategies for care in mental health, because it is based on a clinic that welcomes, encourages the formation of bonds and promotes the continuity of care to the user. This study aims to identify the scientific evidence on the development of the Singular Therapeutic Project in mental health. This is an integrative literature review, from July to October 2022. To formulate the research question, the strategy of the acronym PICo was used, resulting in the following question: what is the scientific evidence on the development of the Singular Therapeutic Project in Mental Health? The results found point out that it has potentialities and challenges regarding its development in the mental health field. The shared care and the formation of a bond with the user were presented as important factors for the development of the instrument. It is understood that innovations in mental health care, such as the expanded clinic and the development of the Singular Therapeutic Project, enable the social inclusion of madness and difference in different spaces of the social and cultural context.

El Proyecto Terapéutico Singular es una de las principales estrategias de atención en salud mental, ya que se basa en una clínica que acoge, apuesta por la formación de vínculos y promueve la continuidad asistencial al usuario. Este estudio tiene como objetivo identificar la evidencia científica sobre el desarrollo del Proyecto Terapéutico Singular en salud mental. Se trata de una revisión bibliográfica integradora, realidad en el período de julio a octubre de 2022. Para formular la pregunta de investigación, se utilizó la estrategia del acrónimo PICo, resultando en la siguiente pregunta: ¿cuál es la evidencia científica sobre el desarrollo del Proyecto Terapéutico Singular en Salud Mental? Los resultados encontrados indican que tiene potencialidades y desafíos en cuanto a su desarrollo en salud mental. El cuidado compartido y la formación de vínculo con el usuario se presentaron como factores importantes para el desarrollo del instrumento. Se entiende que innovaciones en la atención a la salud mental, como la clínica ampliada y el desarrollo del Proyecto Terapéutico Singular, permiten la inclusión social de la locura y de la diferencia en diferentes espacios del contexto social y cultural.

Análise econômica dos planos de saúde: há racionalidade na regulação indutora de saúde suplementar preventiva? / Economic analysis of private health and insurance plans: is there rationality in the regulation that induces preventive strategy?

Objetivo: Analisar a regulação setorial de saúde suplementar e refletir sobre a racionalidade de uma regulação indutora de saúde preventiva. Métodos: Foi feita uma descrição do mercado de planos de saúde brasileiro a partir de uma concepção de análise econômica do direito. Em seguida, foram descritos os impactos no modelo econômico desenvolvido resultantes da adoção de uma assistência voltada à saúde preventiva. Finalmente, foi avaliada a regulação indutora de saúde preventiva. Resultados: Há racionalidade no desenvolvimento de programas de promoção de saúde e prevenção de doenças por operadoras de planos de saúde. A disseminação do modelo, entretanto, envolve fatores como a gestão em saúde, a disponibilidade de equipe especializada e, sobretudo, a regulação em saúde suplementar. Este último fator, por meio do exercício de funções normativas e fiscalizatórias, pode ser capaz de induzir o mercado para um modelo de saúde preventiva. Conclusão: Em que pese a teoria econômica indicar a racionalidade da implantação de um modelo assistencial com foco de saúde preventiva, verifica-se que o mercado de saúde suplementar brasileiro não se desenvolveu nesse sentido. É esperado que a regulação estatal seja uma ferramenta de indução a um modelo assistencial que seja benéfico aos agentes do mercado, o que ainda não ocorreu no caso em análise.

Objective: To analyze the sectorial regulation of supplementary health and to reflect on the rationality of a health regulation that induces the prevention of diseases. Methods: A description of the Brazilian health insurance market was presented based on the economic analysis of the law. Next, the economic impacts of adopting preventive health care were described. Finally, preventive health-inducing regulation was evaluated. Results: There is rationality in the development of health promotion and disease prevention programs by health plan operators. The dissemination of the model, however, involves factors such as health management, the availability of a specialized team and, above all, regulation in supplementary health. This last factor, through the exercise of normative and supervisory functions, may be able to induce the market towards a preventive health model. Conclusion: Despite the economic theory indicating the rationality of implementing a care model with a focus on preventive health, it appears that the Brazilian supplementary health market has not developed in this sense. It is expected that state regulation will be a tool to induce a care model that is beneficial to market agents, which has not yet occurred in the case under analysis.

Factors Associated With PIM use in the Frail Elderly: A Cross-sectional Study.

Background: The use of potentially inappropriate medications (PIM) by the elderly is commonly studied, but studies evaluating the use of PIM by frail elderly covered by prepaid health plans are still lacking. Objective: To identify the prevalence of use and the factors associated with the use of PIM by the elderly patients with high and moderate risk of clinical-functional vulnerability, according to the Beers criteria 2019. Methods: A cross-sectional study was developed with elderly people from a private health plan in Vitória-ES, Brazil. Socioeconomic, demographic and clinical data were collected through a digital platform and a structured questionnaire through an interview, from October 2018 to June 2019. The association between the use of PIM and independent variables was verified by univariate logistic regression with their respective confidence intervals (CI) 95%. The Multiple Model included the variables with P ≤ .20. Results: 332 elderly patients were interviewed (mean age 81.5 years, gender 237 female, 95 male). A 65% prevalence of PIM use was identified. In the multiple logistic regression model, the variables associated with the use of PIM were self-medication (P = .004), high risk of clinical-functional vulnerability (P = .022), use of psychotropic medications (P = .000001), musculoskeletal medications (P = .04) and alimentary tract medications (P = .03). Physical exercises were considered a protection factor (P = .02). Conclusion: The high prevalence of PIM use indicates the need for improvement in elderly private health care, to increase pharmacotherapy safety for this population.

High deductible health plans and spending among families with a substance use disorder.

BACKGROUND: The United States faces an ongoing drug crisis, worsened by the undertreatment of substance use disorders (SUDs). Family enrollment in high deductible health plans (HDHPs) and the resulting increased cost exposure could exacerbate the undertreatment of SUD. This study characterized the distribution of health care spending within families where a member has a SUD and estimated the association between HDHPs and family health care spending. METHODS: Using commercial claims and enrollment data from OptumLabs (2007-2017), we identified a treatment group of enrollees whose employers began offering an HDHP and comparison group whose employers never offered an HDHP. We used a difference-in-differences analysis that compared health care spending in families at firms that did vs. did not offer an HDHP before and after the HDHP offer. All models were adjusted for employer and year fixed effects, as well as family demographics, size, and chronic conditions. RESULTS: Our sample was comprised of 317,353 family-years. Family members with a SUD, on average, contributed an outsized proportion of total family health care expenditures (56.9% in a family of three). Offering a family HDHP was associated with a 6.1% reduction (95% confidence interval [CI]: 9.7-2.6%) in the probability of families having any SUD-related expenditures. The HDHP offer was associated with a $1546 reduction in family total expenditures and a $1185 reduction for the individual with SUD (95% CI: -2272 to -821 and -1845 to -525, respectively). CONCLUSIONS: The increased prevalence of family enrollment in HDHPs may further the existing issue of undertreatment of SUDs.

COVID-19 Vaccine Acceptors, Refusers, and the Moveable Middle: A Qualitative Study from Central Texas.

COVID-19 has caused excessive morbidity and mortality worldwide. COVID-19 vaccines, including the two mRNA vaccines, were developed to help mitigate COVID-19 and to move society towards herd immunity. Despite the strong efficacy and effectiveness profile of these vaccines, there remains a degree of vaccine hesitancy among the population. To better understand hesitancy associated with COVID-19 vaccines and to delineate between those who are vaccine acceptors, vaccine refusers, and the moveable middle, we conducted a cross-sectional survey to understand respondents' decision to receive, or not, a COVID-19 vaccine at the onset of mRNA vaccine availability in Central Texas. A total of 737 individuals responded, with 685 responses classified to one of eight domains: A: End to the Pandemic (n = 48); B: Trust in Medical Community (n = 27); C: Illness-Focused Perceptions (n = 331); D: Social Motivation (n = 54); E: Vaccine-Focused Perceptions (n = 183); F: Knowledge Gap (n = 14); G: Underlying Health Concern (n = 9); and H: Undecided (n = 19). Vaccine acceptors (n = 535) were primarily represented in domains A-E, while vaccine refusers (n = 26) were primarily represented in domains C, E, G, and H. The moveable middle (n = 124) was primarily represented by domains C-H. These findings show clear delineations between vaccine acceptors, vaccine refusers, and the moveable middle across eight domains that can assist public health professionals in addressing vaccine hesitancy.

[Health insurance scheme: main contributor to inequalities in COVID-19 mortality in ColombiaTipo de cobertura de assistência à saúde: o principal fator contribuinte para as desigualdades em mortalidade por COVID-19 na Colômbia]. / Plan de seguro de salud: factor que más contribuye a las desigualdades en la mortalidad por COVID-19 en Colombia.

Objectives: To quantify socioeconomic inequalities in COVID-19 mortality in Colombia and to assess the extent to which type of health insurance, comorbidity burden, area of residence, and ethnicity account for such inequalities. Methods: We analyzed data from a retrospective cohort of COVID-19 cases. We estimated the relative and slope indices of inequality (RII and SII) using survival models for all participants and stratified them by age and gender. We calculated the percentage reduction in RII and SII after adjustment for potentially relevant factors. Results: We identified significant inequalities for the whole cohort and by subgroups (age and gender). Inequalities were higher among younger adults and gradually decreased with age, going from RII of 5.65 (95% confidence interval [CI] = 3.25, 9.82) in participants younger than 25 years to RII of 1.49 (95% CI = 1.41, 1.58) in those aged 65 years and older. Type of health insurance was the most important factor, accounting for 20% and 59% of the relative and absolute inequalities, respectively. Conclusions: Significant socioeconomic inequalities exist in COVID-19 mortality in Colombia. Health insurance appears to be the main contributor to those inequalities, posing challenges for the design of public health strategies.

Objetivos: Quantificar as desigualdades socioeconômicas na mortalidade por COVID-19 na Colômbia e avaliar até que ponto o tipo de cobertura de assistência à saúde, a carga de comorbidades, o local de residência e a etnia contribuíram para tais desigualdades. Métodos: Analisamos dados de uma coorte retrospectiva de casos de COVID-19. Calculamos os índices relativo e angular de desigualdade (RII e SII, respectivamente) utilizando modelos de sobrevivência em todos os participantes, estratificando-os por idade e gênero. Calculamos o percentual de redução no RII e no SII após ajuste para fatores possivelmente relevantes. Resultados: Identificamos desigualdades significativas na coorte como um todo e por subgrupos (idade e gênero). As desigualdades foram maiores para adultos mais jovens e decaíram gradualmente com a idade, indo de um RII de 5,65 (intervalo de confiança [IC] de 95% = 3,25; 9,82] nos participantes com idade inferior a 25 anos a um RII de 1,49 [IC 95% = 1,41; 1,58] nas pessoas com 65 anos ou mais. O tipo de cobertura de assistência à saúde foi o fator mais importante, representando 20% e 59% das desigualdades relativa e absoluta, respectivamente. Conclusões: Desigualdades socioeconômicas significativas afetaram a mortalidade por COVID-19 na Colômbia. O tipo de cobertura de saúde parece ser o principal fator contribuinte para essas desigualdades, impondo desafios à elaboração de estratégias de saúde pública.

Impacto del diagnóstico prenatal del Programa Nacional para la Prevención de Anemia Falciforme en la incidencia de hemoglobinopatías en Santiago de Cuba / Impact of the prenatal diagnosis of the National Program for the prevention of sickle-cell anemia in the incidence of hempoglobimopathies in Santiago de Cuba

Introducción: El nacimiento de personas con hemoglobinas SS y SC promovió la creación en Cuba de un programa de prevención que incluye el diagnóstico prenatal de estas hemoglobinopatías. Objetivo: Mostrar el impacto del diagnóstico prenatal en la incidencia de anemia drepanocítica y de enfermedad heterocigótica compuesta SC. Métodos: Se realizó un estudio descriptivo, retrospectivo, de corte transversal, en el Departamento Provincial de Genética Médica del Hospital Docente Infantil Sur Dr. Antonio María Béguez César en Santiago de Cuba, que abarcó un período de tres decenios más un sexenio (de 1984 a 2019), de los 713 fetos y niños en los que se detectó anemia de células falciformes. Para establecer el diagnóstico prenatal se realizó electroforesis de hemoglobina a las embarazadas -durante los primeros años con el equipo Habana y a partir del 2012 con la tecnología Hydrasys-. Resultados: Del total de casos diagnosticados, se interrumpió el embarazo en 44,3 %, con un incremento significativo de los abortos provocados por esta causa al transcurrir los años, a saber: 23,7 % en el primer decenio, 46,1 % en el segundo y 68,1 % en el tercero; mientras que en el período 2014-2019 fue de 59,3 %. Por consiguiente, disminuyó el nacimiento de niños enfermos de 76,3 % en los inicios del estudio a 53,9 y 31,9 % en el segundo y tercero decenios, respectivamente, y por último a 40,7 % en el sexenio. Conclusiones: El diagnóstico prenatal de la anemia de células falciformes SS y la enfermedad heterocigótica compuesta SC constituye el pilar fundamental para la prevención de estas hemoglobinopatías.

Introduction: The birth of people with SS and SC hemoglobine justified the creation of a prevention program in Cuba which includes the antenatal diagnosis of these hemoglobinopathies. Objective: To show the impact of the antenatal diagnosis in the incidence of sickle-cell anemia and of the composed heterocigotic disease SC. Methods: A descriptive restrospective and cross-sectional study was carried out in the Provincial Department of the Teaching Southern Pediatric Hospital Antonio María Béguez César in Santiago de Cuba, which included three decades and a sexennium (from 1984 to 2019), of the 713 fetuses and children in whom sickell-cell anemia was diagnosed. To establish the prenatal diagnosis, hemoglobine electrophoresis to all pregnant women, -During the first years with Havana equipment and from 2012 on, with the technology Hydrasys-. Results: From the total of diagnosed cases, pregnancy was interrupted in 44,3 %, with a significant increase of aborptions provoked due to this cause with the passing of years: 23.7 % in the first decenium, 46.1 in the second and 68.1 % in the third, while in the period 2014-2019 it was 59.3 %. Due to this, the births of sick children to from 76.3 % at the beggining of the study to 53.9 and 31.9 respectively, and finally to 40.7 % in the sexenium 2014-2019. Conclusions: The prenatal diagnosis of sickel-cell anemia SS and SC constitutes the key stone for the prevention of these hemoglobinopathies.

Twelve month oral contraceptive pill prescriptions: Role of policy mandates on utilization.

Recent studies have suggested that extended duration oral contraceptive pills (OCP), such as the 12-month duration, have a positive impact on pregnancy rates but negative impact on pill wastage. Several states have since been mandating health plans to offer extended duration OCP as an option for women. The objective of the study was to evaluate the impact of these mandates on utilization of extended duration OCPs. Using claims data of a large pharmacy benefit manager for commercially insured women from 2018 to 2019, use, adherence, continuity, and wastage of OCPs by women dispensed one-month only, three-months only, 6 or 12-months only, and other months (which includes other months and mixed duration OCP) was retrospectively analyzed. OCP dispensed by year, and adherence, continuity, wastage over a 15-month period were summarized using Chi square and ANOVA. There were 874,420 and 875,914 women in this study in 2018 and 2019 respectively. Of these, 34% were from states with the mandate (SWM). Most women filled the one-month and three-month duration, with very low overall 6 or 12-month duration claims. Proportion of utilizers of 6 or 12- month duration was higher in SWM than in those without, although differences in absolute rates were very low. Patients with OCP discontinuation, gaps ≥7 and 14 days, were fewer among those filling 6 or 12-month duration but conversely, wastage was higher in this group compared to those filling one or three-month duration. Our findings suggest that, among commercially insured women, extended duration OCP mandates have so far not had much influence on use of 6 or 12-month duration OCP prescriptions.

Considerations When Aggregating Data to Measure Performance Across Levels of the Health Care System.

BACKGROUND: Measuring quality at varying levels of the health care system requires attribution, a process of determining the patients and services for which each level is responsible. However, it is important to ensure that attribution approaches are equitable; otherwise, individuals may be assigned differentially based upon social determinants of health. METHODS: First, we used Medicaid claims (2010-2018) from Michigan to assess the proportion of children with sickle cell anemia who had less than 12 months enrollment within a single Medicaid health plan and could therefore not be attributed to a specific health plan. Second, we used the Medicaid Analytic eXtract data (2008-2009) from 26 states to simulate adapting the 30-Day Pediatric All-Condition Readmission measure to the Accountable Care Organization (ACO) level and examined the proportion of readmissions that could not be attributed. RESULTS: For the sickle cell measure, an average of 300 children with sickle cell anemia were enrolled in Michigan Medicaid each year. The proportion of children that could not be attributed to a Medicaid health plan ranged from 12.2% to 89.0% across years. For the readmissions measure, of the 1,051,365 index admissions, 22% were excluded in the ACO-level analysis because of being unable to attribute the patient to a health plan for the 30 days post discharge. CONCLUSIONS: When applying attribution models, it is essential to consider the potential to induce health disparities. Differential attribution may have unintentional consequences that deepen health disparities, particularly when considering incentive programs for health plans to improve the quality of care.